These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23123021)

  • 21. Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine.
    Hu Y; Smith D; Zhao Z; Harmon T; Pentel PR; Ehrich M; Zhang C
    Nanomedicine; 2019 Aug; 20():102023. PubMed ID: 31181264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge.
    Park S; Lee Y; Kwon YM; Lee YT; Kim KH; Ko EJ; Jung JH; Song M; Graham B; Prausnitz MR; Kang SM
    PLoS One; 2018; 13(10):e0205071. PubMed ID: 30365561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes.
    Fraleigh NL; Oliva R; Lewicky JD; Martel AL; Acevedo R; Dagmar GR; Le HT
    PLoS One; 2019; 14(8):e0221708. PubMed ID: 31442285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.
    Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH
    Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging adjuvants for intradermal vaccination.
    Chen X
    Int J Pharm; 2023 Feb; 632():122559. PubMed ID: 36586639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.
    Le HT; Fraleigh NL; Lewicky JD; Boudreau J; Dolinar P; Bhardwaj N; Diaz-Mitoma F; Montaut S; Fallahi S; Martel AL
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32178357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
    Ko EJ; Lee Y; Lee YT; Kim YJ; Kim KH; Kang SM
    Antiviral Res; 2018 Aug; 156():107-115. PubMed ID: 29885376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
    Mazumder S; Maji M; Ali N
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
    Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
    Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel laser vaccine adjuvant increases the motility of antigen presenting cells.
    Chen X; Kim P; Farinelli B; Doukas A; Yun SH; Gelfand JA; Anderson RR; Wu MX
    PLoS One; 2010 Oct; 5(10):e13776. PubMed ID: 21048884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive markers of safety and immunogenicity of adjuvanted vaccines.
    Mastelic B; Garçon N; Del Giudice G; Golding H; Gruber M; Neels P; Fritzell B
    Biologicals; 2013 Nov; 41(6):458-68. PubMed ID: 24071553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
    Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
    Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.
    McCluskie MJ; Thorn J; Gervais DP; Stead DR; Zhang N; Benoit M; Cartier J; Kim IJ; Bhattacharya K; Finneman JI; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Dec; 29(2):663-671. PubMed ID: 26404190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.
    Hui GS; Hashimoto CN
    Int Immunopharmacol; 2008 Jul; 8(7):1012-22. PubMed ID: 18486913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term regulation of local cytokine production following immunization in mice.
    Nakayama T; Kashiwagi Y; Kawashima H
    Microbiol Immunol; 2018 Feb; 62(2):124-131. PubMed ID: 29266448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct Effects of Monophosphoryl Lipid A, Oligodeoxynucleotide CpG, and Combination Adjuvants on Modulating Innate and Adaptive Immune Responses to Influenza Vaccination.
    Ko EJ; Lee YT; Lee Y; Kim KH; Kang SM
    Immune Netw; 2017 Oct; 17(5):326-342. PubMed ID: 29093654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulation Effects and Mechanisms of Different Adjuvants on a Norovirus P Particle-Based Active Amyloid-β Vaccine.
    Dai M; Feng X; Mo Z; Sun Y; Fu L; Zhang Y; Wu J; Yu B; Zhang H; Yu X; Wu H; Kong W
    J Alzheimers Dis; 2020; 77(4):1717-1732. PubMed ID: 32925038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins.
    Zhao Z; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C
    Nanomedicine; 2018 Jul; 14(5):1655-1665. PubMed ID: 29719216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [